1
|
Levaillant L, Huet F, Bretones P, Corne C, Dupuis C, Reynaud R, Somma C, Barat P, Corcuff J, Bouhours-Nouet N, Gauthereau V, Polak M, Leger J, Cheillan D, Coutant R. Neonatal screening for congenital hypothyroidism: Time to lower the TSH threshold in France. Arch Pediatr 2022; 29:253-257. [DOI: 10.1016/j.arcped.2022.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 12/20/2021] [Accepted: 02/04/2022] [Indexed: 10/18/2022]
|
2
|
Azar C, Cheillan D, Nadjar Y. Unusual early‐onset and severe adrenomyeloneuropathy in women. Eur J Neurol 2020; 27:e73. [DOI: 10.1111/ene.14297] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 04/28/2020] [Indexed: 11/28/2022]
Affiliation(s)
- C. Azar
- Neurology Department Reference Center for Lysosomal disease Neuro‐Genetics and Metabolism Unit Pitié‐Salpêtrière Hospital ParisFrance
| | - D. Cheillan
- Unité Maladies Héréditaires du Métabolisme Service de Biochimie et Biologie Moléculaire Grand Est Centre de Biologie et de Pathologie Est Hospices Civils de Lyon Lyon France
| | - Y. Nadjar
- Neurology Department Reference Center for Lysosomal disease Neuro‐Genetics and Metabolism Unit Pitié‐Salpêtrière Hospital ParisFrance
| |
Collapse
|
3
|
Barry Y, Mandereau-Bruno L, Bonaldi C, Guseva-Canu I, Delmas D, Cheillan D, Roussey M, Coutant R, Léger J, Regnault N. Surveillance of transient congenital hypothyroidism using the French newborn screening programme. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Congenital hypothyroidism (CH) is a condition of thyroid hormone deficiency present at birth. Untreated CH results in severe mental impairment. An increased incidence of CH has been reported in France and worldwide that could be explained by an increase in transient forms of CH (TCH). We aimed to estimate the proportion of transient eutopic gland based on the characteristics of children at birth.
Methods
A probabilistic matching data from French CH neonatal screening program and French national health data system (SNDS) of children born between 2006 and 2012 (1, 763 with CH) allowed to linking 484 (68.8%) among 703 children with eutopic gland. Infants with six months or greater discontinuation of levothyroxine (LT4) treatment before the 31th December 2017 were classified transient CH. We used the Cox model to examine the predictors of TCH.
Results
Among infants with eutopic gland, 52.9% were female, 14.9% were preterm and 14, 1 % had low birth weight, 11.8 % had a first degree family history of thyroid diseases, 48.1% of mild CH (TSH<50mU/L) at diagnosis and 30,0μg/j median dose of LT4 treatment. The probability of transient CH at five years of follow-up was 25.3% [IC95%:21.6% -29.4%] and 36.7% [31.7% -42.2%] after ten years. In a cox multivariable analysis, neonates with a TSH<50mU/L (adjusted Hazard Ratio=4.1 [2.8-6.2]) and preterm 1.9 [1.1-3.4] had more risk to be transient.
Conclusions
Prematurity and TSH level were predictors of transient CH. Additional analyses are ongoing to determine whether the occurrence of transient forms of TCH is increasing over the study period.
Key messages
Transient congenital hypothyroidism represent a significant part of HC at 10 years of follow-up. This finding has important implication on medical practices and should trigger research on the etiology of these transient forms.
Collapse
Affiliation(s)
- Y Barry
- Non-Communicable Diseases and Trauma Division, Santé Publique France, Saint-Maurice, France
| | - L Mandereau-Bruno
- Direction Appui, Traitements et Analyses de Données, Santé Publique France, Saint-Maurice, France
| | - C Bonaldi
- Direction Appui, Traitements et Analyses de Données, Santé Publique France, Saint-Maurice, France
| | - I Guseva-Canu
- Non-Communicable Diseases and Trauma Division, Santé Publique France, Saint-Maurice, France
| | - D Delmas
- Association Française pour le Dépistage et la Prévention des Handicaps de l’enfant, Paris, France
| | - D Cheillan
- Association Française pour le Dépistage et la Prévention des Handicaps de l’enfant, Paris, France
- Hospices Civils de Lyon, Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et de Pathologie Est, Lyon, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U.1060, Université Lyon-1, Lyon, France
| | - M Roussey
- Association Française pour le Dépistage et la Prévention des Handicaps de l’enfant, Paris, France
| | - R Coutant
- Association Française pour le Dépistage et la Prévention des Handicaps de l’enfant, Paris, France
- CHU-Angers, Unité Endocrinologie Diabétologie Pédiatrique and Centre des Maladies Rares de la Réceptivité Hormonale, Angers, France
| | - J Léger
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service d’Endocrinologie-Diabétologie Pédiatrique, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France
- Université de Paris, Paris, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1141, DHU Protect, Paris, France
| | - N Regnault
- Non-Communicable Diseases and Trauma Division, Santé Publique France, Saint-Maurice, France
| |
Collapse
|
4
|
Boulet M, Cheillan D, Di Filippo M, Michalski M, Moulin P, Calzada C. Triglyceride Rich Lipoproteins From Type 2 Diabetic Patients Activate Platelets. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Boulet MM, Cheillan D, Di Filippo M, Buisson C, Michalski MC, Moulin P, Calzada C. Large triglyceride-rich lipoproteins from fasting patients with type 2 diabetes activate platelets. Diabetes Metab 2019; 46:54-60. [PMID: 30981822 DOI: 10.1016/j.diabet.2019.03.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 03/25/2019] [Accepted: 03/30/2019] [Indexed: 01/06/2023]
Abstract
AIMS Type 2 diabetes (T2D) patients present with risk factors for atherothrombosis such as fasting hypertriglyceridaemia and platelet hyperactivity. Our study objective was to determine the effect of large triglyceride-rich lipoproteins (TGRL) from fasting T2D patients on platelet aggregation and, if any, to identify the signaling pathway involved. METHODS Large TGRL were isolated from the plasma of 25 T2D patients by ultracentrifugation (density < 1.000 g/mL). Platelets were isolated from healthy blood donors (HBD) and suspended in buffer, then preincubated in the presence or absence of TGRL and stimulated with either collagen or thrombin. Platelet aggregation and the arachidonic acid (AA) signaling pathway were studied. RESULTS Fasting T2D large TGRL were mostly of hepatic origin (apoB100/apoB48 ratio: 42 ± 7) and rich in triglycerides (TG/total apoB ratio: 4.2 ± 0.5), and able to potentiate agonist-stimulated platelet aggregation (collagen: +68%, P < 0.05; thrombin: +771%, P < 0.05). It should also be mentioned that TGRL from the plasma of HBD (n = 7) had no effect on platelet aggregation. In addition, T2D large TGRL increased thromboxane B2 (TxB2) concentration in platelets stimulated with either collagen (+34%, P < 0.05) or thrombin (+37%, P < 0.05) compared with platelets stimulated with either of these agonists without TGRL. Phosphorylation of p38 MAPK and cytosolic phospholipase A2 (cPLA2) was enhanced after incubation of platelets with T2D TGRL and thrombin (+87% and +32%, respectively, P < 0.05) compared with platelets incubated with thrombin only. CONCLUSION Large TGRL from fasting T2D patients may play a role in the development of atherothrombosis by increasing platelet aggregation and activating the platelet AA signaling pathway.
Collapse
Affiliation(s)
- M M Boulet
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France
| | - D Cheillan
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France; Laboratoire de biochimie et de biologie moléculaire Grand Est, centre de biologie et de pathologie Est, hospices civils de Lyon, 69677 Bron, France
| | - M Di Filippo
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France; Laboratoire de biochimie et de biologie moléculaire Grand Est, centre de biologie et de pathologie Est, hospices civils de Lyon, 69677 Bron, France
| | - C Buisson
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France
| | - M-C Michalski
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France
| | - P Moulin
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France; Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, hôpital Louis-Pradel, hospices civils de Lyon, 69677 Bron, France
| | - C Calzada
- Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, INSA Lyon, université Claude-Bernard Lyon 1, IMBL, 69621 Villeurbanne, France.
| |
Collapse
|
6
|
Benjelloun FZM, Kriouile Y, Cheillan D, Daoud-Tetouani H, Chabraoui L. Management of X-linked adrenoleukodystrophy in Morocco: actual situation. BMC Res Notes 2017; 10:567. [PMID: 29116030 PMCID: PMC5678772 DOI: 10.1186/s13104-017-2902-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 11/01/2017] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES X-linked adrenoleukodystrophy is a neurodegenerative disorder caused by mutations in the ABCD1 gene. Adrenomyeloneuropathy and childhood cerebral Adrenoleukodystrophy are the most common phenotypes. This paper focuses on a descriptive study of the first program of diagnosis, treatment, and follow-up of this disease in Morocco. RESULTS We developed three protocols of X-linked Adrenoleukodystrophy management: general protocol, asymptomatic protocol, and heterozygous protocol. Over a period of 5 years, we recruited eight families with 16 patients. Clinically, the presentation is primary adrenal insufficiency and behavioral changes. All patients had elevated levels of very long fatty acids. This is the first study of X-linked adrenoleukodystrophy in Morocco. It shows the importance of this metabolic disease and broadens perspectives in terms of its diagnosis and its treatment.
Collapse
Affiliation(s)
- F Z Madani Benjelloun
- Biochemistry Laboratory, Faculty of Medicine and Pharmacy, University Mohammed V Souissi, Rabat, Morocco.
| | - Y Kriouile
- Neuropediatric Department, Children's Hospital, Rabat, Morocco
| | - D Cheillan
- Department of Inherited and Metabolic Diseases and Neonatal Screening, Hospices Civils , Lyon, France
| | - H Daoud-Tetouani
- Department of Biomedical Engineering, Bunker Hill Community College, Boston, USA
| | - L Chabraoui
- Biochemistry Laboratory, Faculty of Medicine and Pharmacy, University Mohammed V Souissi, Rabat, Morocco.,Central Laboratory of Inherited and Metabolic Diseases, Ibn Sina Hospital, Rabat, Morocco
| |
Collapse
|
7
|
Dimassi S, Labalme A, Ville D, Calender A, Mignot C, Boutry-Kryza N, de Bellescize J, Rivier-Ringenbach C, Bourel-Ponchel E, Cheillan D, Simonet T, Maincent K, Rossi M, Till M, Mougou-Zerelli S, Edery P, Saad A, Heron D, des Portes V, Sanlaville D, Lesca G. Whole-exome sequencing improves the diagnosis yield in sporadic infantile spasm syndrome. Clin Genet 2015; 89:198-204. [PMID: 26138355 DOI: 10.1111/cge.12636] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Revised: 06/13/2015] [Accepted: 06/29/2015] [Indexed: 12/25/2022]
Abstract
Infantile spasms syndrome (ISs) is characterized by clinical spasms with ictal electrodecrement, usually occurring before the age of 1 year and frequently associated with cognitive impairment. Etiology is widely heterogeneous, the cause remaining elusive in 40% of patients. We searched for de novo mutations in 10 probands with ISs and their parents using whole-exome sequencing (WES). Patients had neither consanguinity nor family history of epilepsy. Common causes of ISs were excluded by brain magnetic resonance imaging (MRI), metabolic screening, array-comparative genomic hybridization (CGH) and testing for mutations in CDKL5, STXBP1, and for ARX duplications. We found a probably pathogenic mutation in four patients. Missense mutations in SCN2A (p.Leu1342Pro) and KCNQ2 (p.Ala306Thr) were found in two patients with no history of epilepsy before the onset of ISs. The p.Asn107Ser missense mutation of ALG13 had been previously reported in four females with ISs. The fourth mutation was an in-frame deletion (p.Phe110del) in NR2F1, a gene whose mutations cause intellectual disability, epilepsy, and optic atrophy. In addition, we found a possibly pathogenic variant in KIF3C that encodes a kinesin expressed during neural development. Our results confirm that WES improves significantly the diagnosis yield in patients with sporadic ISs.
Collapse
Affiliation(s)
- S Dimassi
- Department of Medical Genetics, Lyon University Hospital, Lyon, France.,CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France.,Claude Bernard Lyon I University, University of Lyon, Lyon, France.,Cytogenetics and Reproductive Biology Department, Farhat Hached University Teaching Hospital, Sousse, Tunisia.,Common Service Units for Research in Genetics, Faculty of Medicine of Sousse, Avenue Mohamed Karoui, University of Sousse, Tunisia
| | - A Labalme
- Department of Medical Genetics, Lyon University Hospital, Lyon, France
| | - D Ville
- Department of Neuropediatrics, Lyon University Hospital, Lyon, France
| | - A Calender
- Claude Bernard Lyon I University, University of Lyon, Lyon, France.,Department of Molecular Genetics, Lyon University Hospital, Lyon, France
| | - C Mignot
- Département de Génétique et Centre de Référence "Déficiences intellectuelles de causes rares", AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Department of Pediatric Neurophysiology, Amiens University Hospital, Amiens, France
| | - N Boutry-Kryza
- CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France.,Claude Bernard Lyon I University, University of Lyon, Lyon, France.,Department of Molecular Genetics, Lyon University Hospital, Lyon, France
| | - J de Bellescize
- Epilepsy, Sleep and Pediatric Neurophysiology Department, Lyon University Hospital, Lyon, France
| | - C Rivier-Ringenbach
- Department of Pediatrics, Nord-Ouest Hospital, Villefranche-sur-Saone, France
| | - E Bourel-Ponchel
- Department of Pediatric Neurophysiology, Amiens University Hospital, Amiens, France
| | - D Cheillan
- Claude Bernard Lyon I University, University of Lyon, Lyon, France.,Service des Maladies Héréditaires du métabolisme, INSERM U1060, Lyon University Hospital, Lyon, France
| | - T Simonet
- Department of Cell Biotechnology, ENS Lyon, Lyon University Hospital, Lyon, France
| | - K Maincent
- Department of Pediatric Neurology, Hôpital Trousseau, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - M Rossi
- Department of Medical Genetics, Lyon University Hospital, Lyon, France.,CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France
| | - M Till
- Department of Medical Genetics, Lyon University Hospital, Lyon, France
| | - S Mougou-Zerelli
- Cytogenetics and Reproductive Biology Department, Farhat Hached University Teaching Hospital, Sousse, Tunisia.,Common Service Units for Research in Genetics, Faculty of Medicine of Sousse, Avenue Mohamed Karoui, University of Sousse, Tunisia
| | - P Edery
- Department of Medical Genetics, Lyon University Hospital, Lyon, France.,CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France.,Claude Bernard Lyon I University, University of Lyon, Lyon, France
| | - A Saad
- Cytogenetics and Reproductive Biology Department, Farhat Hached University Teaching Hospital, Sousse, Tunisia.,Common Service Units for Research in Genetics, Faculty of Medicine of Sousse, Avenue Mohamed Karoui, University of Sousse, Tunisia
| | - D Heron
- Département de Génétique et Centre de Référence "Déficiences intellectuelles de causes rares", AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,GRC-Génétique des Déficiences Intellectuelles de Causes rares, Université Pierre et Marie Curie, Paris, France
| | - V des Portes
- Department of Neuropediatrics, Lyon University Hospital, Lyon, France.,Department of Molecular Genetics, Lyon University Hospital, Lyon, France.,Reference Center for Tuberous Sclerosis and Rare Epileptic Syndromes, Lyon University Hospital, Lyon, France
| | - D Sanlaville
- Department of Medical Genetics, Lyon University Hospital, Lyon, France.,CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France.,Claude Bernard Lyon I University, University of Lyon, Lyon, France
| | - G Lesca
- Department of Medical Genetics, Lyon University Hospital, Lyon, France.,CNRS UMR 5292, INSERM U1028, CNRL, Lyon, France.,Claude Bernard Lyon I University, University of Lyon, Lyon, France
| |
Collapse
|
8
|
Munck A, Audrézet MP, Thauvin-Robinet C, Cheillan D, Delmas D, Girodon E, Roussey M. WS11.6 Newborn screening for cystic fibrosis: Rationale for p.Arg117His (R117H) removal from the CFTR mutation panel in France. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30074-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Roussey M, Cheillan D, Coutant R, Bardakdjian J. Les particularités du « test de Guthrie » en néonatologie. Arch Pediatr 2015; 22:79-80. [DOI: 10.1016/s0929-693x(15)30041-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Barry Y, Goulet V, Coutant R, Cheillan D, Delmas D, Roussey M, Léger J. CO-75 – Augmentation de l'hypothyroïdie congénitale en France: y-a-t-il des facteurs associés? Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30175-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Sarles J, Huet F, Cheillan D, Roussey M. Dépistage néonatal en France : quel avenir ? Arch Pediatr 2014; 21:813-5. [DOI: 10.1016/j.arcped.2014.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Revised: 05/27/2014] [Accepted: 05/27/2014] [Indexed: 11/30/2022]
|
12
|
Nouioua S, Cheillan D, Zaouidi S, Salomons G, Amedjout N, Kessaci F, Boulahdour N, Hamadouche T, Tazir M. Creatine deficiency syndrome. A treatable myopathy due to arginine–glycine amidinotransferase (AGAT) deficiency. Neuromuscul Disord 2013; 23:670-4. [DOI: 10.1016/j.nmd.2013.04.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 04/29/2013] [Indexed: 10/26/2022]
|
13
|
van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, Abulhoul L, Grünewald S, Anselm I, Azzouz H, Bratkovic D, de Brouwer A, Hamel B, Kleefstra T, Yntema H, Campistol J, Vilaseca MA, Cheillan D, D’Hooghe M, Diogo L, Garcia P, Valongo C, Fonseca M, Frints S, Wilcken B, von der Haar S, Meijers-Heijboer HE, Hofstede F, Johnson D, Kant SG, Lion-Francois L, Pitelet G, Longo N, Maat-Kievit JA, Monteiro JP, Munnich A, Muntau AC, Nassogne MC, Osaka H, Ounap K, Pinard JM, Quijano-Roy S, Poggenburg I, Poplawski N, Abdul-Rahman O, Ribes A, Arias A, Yaplito-Lee J, Schulze A, Schwartz CE, Schwenger S, Soares G, Sznajer Y, Valayannopoulos V, Van Esch H, Waltz S, Wamelink MMC, Pouwels PJW, Errami A, van der Knaap MS, Jakobs C, Mancini GM, Salomons GS. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J Med Genet 2013; 50:463-72. [DOI: 10.1136/jmedgenet-2013-101658] [Citation(s) in RCA: 101] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Feillet F, Ogier H, Cheillan D, Aquaviva C, Labarthe F, Baruteau J, Chabrol B, de Lonlay P, Valayanopoulos V, Garnotel R, Dobbelaere D, Briand G, Jeannesson E, Vassault A, Vianey-Saban C. [Medium-chain acyl-CoA-dehydrogenase (MCAD) deficiency: French consensus for neonatal screening, diagnosis, and management]. Arch Pediatr 2012; 19:184-93. [PMID: 22244319 DOI: 10.1016/j.arcped.2011.10.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Accepted: 10/28/2011] [Indexed: 12/30/2022]
Abstract
MCAD deficiency is the most common fatty acid oxidation disorder, with the prevalence varying from 1/10,000 to 1/27,000 in the countries adjacent to France. As the High Authority for Health has recently proposed including MCAD deficiency in the panel of diseases neonatally screened for in France, a consensus was written for the management of MCAD deficiency diagnosed either clinically or by neonatal screening. Patients may present acutely with hyperammonemia, hypoglycemia, encephalopathy, and hepatomegaly, mainly after a prolonged fast of intercurrent infection. Sudden death related to heartbeat disorders may also occur. The diagnosis of MCAD deficiency is suspected on the plasma acylcarnitine and/or the urinary organic acid profile. The diagnosis is confirmed by molecular biology and the enzymatic activity for patients who are not homozygous for the main mutation c.985A>G. However, some MCAD-deficient individuals may remain asymptomatic throughout life. The mainstay of treatment consists in avoiding prolonged fast and prescribing l-carnitine for patients who exhibit a deficiency in plasma carnitine. This management has radically modified the natural history of MCAD deficiency. This consensus will allow homogeneous management of these patients once the neonatal screening of MCAD deficiency has been introduced in France.
Collapse
Affiliation(s)
- F Feillet
- Inserm U 954, centre de référence des maladies héréditaires du métabolisme, hôpital de Brabois-Enfants, rue du Morvan, 54511 Vandœuvre, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
des Georges M, Girodon E, Audrézet M, Bienvenu T, Bieth E, Cheillan D, Iron A, Kitzis A, Lalau G, Malinge M, Houssin E, Roussey M, Munck A. Comprehensive analysis of the French NBS cohort: Excellent mutation detection rate despite high allelic heterogeneity. J Cyst Fibros 2009. [DOI: 10.1016/s1569-1993(09)60022-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Lion L, De La Rochebrochard C, Drouin-Garaud V, Goldenberg A, Acquaviva-Bourdain C, Vianey-Saban C, Marret S, Desportes V, Schulze A, Cheillan D. R - 5 Un nouveau traitement pour les patients atteints du déficit en GAMT. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90752-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Lion-François L, Cheillan D, Pitelet G, Acquaviva-Bourdain C, Bussy G, Cotton F, Guibaud L, Gérard D, Rivier C, Vianey-Saban C, Jakobs C, Salomons GS, des Portes V. High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. Neurology 2006; 67:1713-4. [PMID: 17101918 DOI: 10.1212/01.wnl.0000239153.39710.81] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
MESH Headings
- Adolescent
- Amidinotransferases/genetics
- Brain/enzymology
- Brain/pathology
- Brain/physiopathology
- Brain Diseases, Metabolic, Inborn/complications
- Brain Diseases, Metabolic, Inborn/enzymology
- Brain Diseases, Metabolic, Inborn/genetics
- Child
- Child, Preschool
- Chromosome Disorders/enzymology
- Chromosome Disorders/genetics
- Chromosome Disorders/physiopathology
- Creatine/deficiency
- Creatine/genetics
- Creatinine/metabolism
- DNA Mutational Analysis
- Female
- Genes, Recessive/genetics
- Genetic Diseases, X-Linked/enzymology
- Genetic Diseases, X-Linked/genetics
- Genetic Diseases, X-Linked/physiopathology
- Genetic Predisposition to Disease/genetics
- Genetic Testing
- Guanidinoacetate N-Methyltransferase/genetics
- Humans
- Intellectual Disability/enzymology
- Intellectual Disability/etiology
- Intellectual Disability/genetics
- Magnetic Resonance Spectroscopy
- Male
- Membrane Transport Proteins/genetics
- Prospective Studies
- Sex Factors
Collapse
Affiliation(s)
- L Lion-François
- Service de Neurologie Pédiatrique, Hôpital Debrousse, Hospices Civils de Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Conter C, Rolland MO, Cheillan D, Bonnet V, Maire I, Froissart R. Genetic heterogeneity of the GLDC gene in 28 unrelated patients with glycine encephalopathy. J Inherit Metab Dis 2006; 29:135-42. [PMID: 16601880 DOI: 10.1007/s10545-006-0202-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2005] [Accepted: 10/21/2005] [Indexed: 10/24/2022]
Abstract
Glycine encephalopathy, or nonketotic hyperglycinaemia (NKH; Mckusick 238300) is a severe autosomal recessive disease due to a defect in the glycine cleavage system (GCS), which is a complex of four subunits: P-, T-, H- and L-proteins. A P-protein (glycine decarboxylase or GLDC) deficiency was reported in about 80% of NKH patients. We performed mutation analysis of the complete coding sequence of the GLDC gene in 28 unrelated patients with neonatal NKH using denaturing high-performance liquid chromatography (DHPLC) and sequencing. Forty different gene alterations were identified, confirming the large molecular heterogeneity of the GLDC gene. Eighteen alterations were clearly disease-causing: two large deletions, four one-base deletions (c.28delC, c.1175delC, c.2186delC, c.2422delA), one 1-base insertion (c.1002_1003insT), one 4-base insertion (c.1285_1286insCAAA), one insertion/deletion (c.2153_2155delinsTCCTGGTTTA), five nonsense mutations (p.E153X, p.R236X, p.E270X, p.R337X, p.R424X) and four splice site mutations (c.861+1G > T, c.1402-1C > G, c.2316-1G > A, c.2919+1G > A). Additionally, we identified one intronic mutation outside the consensus splice sites (c.2838+5G > A) and 21 nucleotide substitutions leading to amino acid change (including three previously described mutations: p.T269M, p.R461Q, p.G771R), the pathogenicity of which should be confirmed by expression studies (p.S132W, p.Y138F, p.G171A, p.T187K, p.R212K, p.T269M, p.R373W, p.I440N, p.R461Q, p.N533Y, p.C644F, p.H651R, p.V705M, p.N732K, p.G771R, p.H775R, p.T830M, p.A841P, p.D880V, p.S957P and p.R966G). Mutation analysis allowed us to identify sequence alterations in both alleles for 19 patients and in one allele for 7 patients One patient was carrying three mutations (p.Y138F, p.T269M and p.E153X) and one patient was carrying two amino acid substitutions on the same allele (p.V705M and p.R212K) and an unidentified mutation on the other allele. No mutation could be found in two patients, suggesting possible defects in the H-protein or gene alterations that could not be identified by our technique. The potential use of genotype determination for prenatal diagnosis is emphasized.
Collapse
Affiliation(s)
- C Conter
- Centre d'Etude des Maladies Métaboliques, Hôpital Debrousse, Lyon, France
| | | | | | | | | | | |
Collapse
|
19
|
Froissart R, Cheillan D, Bouvier R, Tourret S, Bonnet V, Piraud M, Maire I. Clinical, morphological, and molecular aspects of sialic acid storage disease manifesting in utero. J Med Genet 2005; 42:829-36. [PMID: 15805149 PMCID: PMC1735939 DOI: 10.1136/jmg.2004.029744] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Sialic acid storage diseases (SASDs) are caused by the defective transport of free sialic acid outside the lysosome. Apart from the Salla presentation in Finland, SASD is a very rare form of lysosomal storage disease (LSD) with approximately 35 cases, all diagnosed after birth, having been reported worldwide. We report a series of 12 French patients with very early manifestations, including eight fetuses diagnosed in utero. RESULTS Ultrasound examination, fetal autopsy, or clinical examination showed prominent ascites, rarely progressing to complete hydrops, and highlighted the early severity of bone disease. Dramatic increase of free sialic acid in various biological samples confirmed the diagnosis in all cases. Storage staining affinities and storage distribution in placenta and fetal organs allowed differential diagnosis from other LSDs but cannot differentiate between SASD, sialidosis, and galactosialidosis. Fourteen different mutations were identified, showing the molecular heterogeneity of SASD in the French population. We found that the previously described p.Y306X mutation generated two different transcripts, and we identified seven novel mutations: three deletions (del exon 7, del exons10+11 and c.1296delT), one splice site mutation (c.1350+1G-->T) one nonsense mutation (p.W339X), and two missense mutations (p.R57C and p.G127E). CONCLUSIONS The severity of our patients' genotypes is in agreement with their phenotypes but not with the importance and early appearance of the very frequent in utero manifestations. Minimal fetal disease in some patients and a reported case of heterogeneity of fetal involvement within a family suggest that factors other than the genotype influence fetal manifestations.
Collapse
Affiliation(s)
- R Froissart
- Centre d'Etude des Maladies Héréditaires du Métabolisme, Hôpital Debrousse, Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
INTRODUCTION Creatine deficiency syndromes are a newly described group of inborn errors of metabolism affecting creatine metabolism. Three diseases have been described: deficiency of arginine: glycine amidinotransferase (AGAT), deficiency of guanidinoacetate methyltransferase (GAMT) and creatine transporter defect (CRTR). STATE OF ART These syndromes are characterized by a depletion of creatine/phosphocreatine in the brain. Clinically, most of the patients develop a variable mental retardation and a severe speech delay associated with epilepsy, extra-pyramidal syndrome and behavior disturbances. These diseases are often diagnosed during infancy but a few adult cases have been reported recently. Diagnosis is established by measurement of guanidinoacetate and creatine in biologic fluids and in vivo proton magnetic resonance spectroscopy by the total lack of intra-cerebral creatine/phosphocreatine demonstrating. GAMT and AGAT deficiencies are treatable by oral creatine supplementation whereas patients with CRTR do not respond to the treatment. CONCLUSION Better knowledge of these syndromes is necessary to optimize diagnosis and patient management of these rare but potentially treatable disorders.
Collapse
Affiliation(s)
- D Cheillan
- Service de Biochimie Pédiatrique, Hôpital Debrousse, 29, rue Soeur-Bouvier, 69322 Lyon, France.
| | | | | | | | | |
Collapse
|
21
|
Cheillan D, Vercherat M, Chevalier-Porst F, Charcosset M, Rolland MO, Dorche C. False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin? J Inherit Metab Dis 2005; 28:813-8. [PMID: 16435172 DOI: 10.1007/s10545-005-0067-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2004] [Accepted: 05/06/2005] [Indexed: 01/27/2023]
Abstract
Since 1979, newborn screening for cystic fibrosis (CF) has been possible by measuring immunoreactive tryspinogen (IRT) in blood spots. In France, a programme based on a three-stage strategy (IRT/DNA/IRT) started in 2002. In the Rhône-Alpes area, the positive screening rate (i.e. the proportion of samples sent for genotyping) observed after the first IRT measurement was higher than the expected rate (0.65% versus 0.50%), without a greater CF incidence. We hypothesized that the IRT reference range could differ according to the ethnic origin of the newborns. 35 141 newborns were studied and divided into two groups: European ethnic group 26 324 (75%) and North African ethnic group 8817 (25%). 243 positive newborns were identified: 146 (60%) in the European ethnic group and 97 (40%) in the North African ethnic group. Three CF patients and 11 unaffected heterozygotes were found in the European group, but no mutations were found in the North African group. Mean IRT values and the percentage of IRT values over the cut-off were significantly higher in the North African group than in the European group (mean IRT = 21.17 microg/L and 19.74 microg/L, p < 0.0001; %IRT > cut-off = 1.1% and 0.5%, respectively). For the positive screened newborns, term and IRT mean were comparable, whereas birth weight was higher in the North African ethnic group. These results lead us to conclude that (i) newborns from families of North African origin have higher IRT values and (ii) most of the positive screened newborns in this population could be considered as 'false positives'. These conclusions could explain, in part, the large variations seen in the positive screening rate in the French CF neonatal screening and raise the question whether it is relevant to adapt cut-off to ethnic origin of the newborns.
Collapse
Affiliation(s)
- D Cheillan
- Service de Biochimie Pédiatrique, Unité de Dépistage Néonatal - Hôpital Debrousse, 29 rue soeur Bouvier, 69005, Lyon, France.
| | | | | | | | | | | |
Collapse
|
22
|
Sassolas A, Cheillan D, Drai J, Bondon PJ, Cartier R. [Should blood samples be drawn on heparin-anticoagulant for lipid analysis?]. Ann Biol Clin (Paris) 2004; 62:583-6. [PMID: 15355810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2004] [Accepted: 05/29/2004] [Indexed: 04/30/2023]
Abstract
Lipid profile is often performed on heparinized-plasma because nothing in particular is explained in the technical data sheet about anticoagulant and because few data (mainly with EDTA anticoagulant) are available in literature. In order to evaluate heparinized-plasma vs serum differences, 50 normo- or hyperlipidemic samples were collected and assayed in 3 clinical laboratories in Lyon on Hitachi analysers with Roche Diagnostic reagents. Lipid values are lower in plasma than in serum; the average negative bias for cholesterol levels is 2 to 4,5% and for triglycerides about 3%, depending on the laboratory; the effect on HDL-cholesterol values is not significant. These results were confirmed by manual procedure on 28 samples with Roche Diagnostic reagent and two similar other reagents (Biomerieux and Randox). A negative bias of 4% on total cholesterol and triglycerides levels is not very important for clinical diagnosis but it is more serious for LDL-cholesterol estimated with Friedewald equation; LDL-cholesterol value needs accuracy because it is a therapeutic goal with statin therapy and an high negative bias (until 0,70 g/L in our results) is unacceptable; moreover, there is a real risk of providing false total cholesterol results. Therefore it is essential to collect blood for lipid profile without any anticoagulant.
Collapse
Affiliation(s)
- A Sassolas
- UF lipides, Laboratoire de biochimie, Hôpital neurologique, Lyon.
| | | | | | | | | |
Collapse
|
23
|
Cheillan D, Cognat S, Vianey-Saban C, Maire I, Dorche C. [Application of tandem mass spectrometry to neonatal screening of inherited metabolic diseases: focus on present developments]. Ann Biol Clin (Paris) 2004; 62:269-77. [PMID: 15217759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
The recent evolution of tandem mass spectrometry allows to diagnose more than twenty inherited metabolic diseases within a single blood spot. Nowadays, it is technically possible to screen newborns for most of fatty acid oxidation, organic acid and amino acid disorders. An important number of prospective pilot studies, using tandem mass spectrometry, have been done worldwide. However, several technical, economical, medical and ethical problems are raised by these applications. This review is intended to focus on this technology and to resume results from the main international studies.
Collapse
Affiliation(s)
- D Cheillan
- Service de biochimie pédiatrique, Hôpital Debrousse, Lyon.
| | | | | | | | | |
Collapse
|
24
|
Abstract
Congenital disorders of glycosylation (CDG) are a group of genetic diseases characterized by defective protein glycosylation. N-glycosylation defects are divided into two groups (I and II). CDG group II (types IIa to IIe) refers to defects in the Golgi processing of protein-bound glycans. We report a patient with CDG IIx and an unusual phenotype.
Collapse
Affiliation(s)
- D Cheillan
- Service de Biochimie Pédiatrique, Hôpital Debrousse, Lyon, France.
| | | | | | | | | | | |
Collapse
|
25
|
Cheillan D, Bancel J, Tiliket C, Savet J, Caudie C, Later R, Vighetto A. [A surprising aglycorrachia! A case of neurocysticercosis]. Ann Biol Clin (Paris) 1999; 57:356-9. [PMID: 10377490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- D Cheillan
- Service de biologie, Hôpital neurologique, Lyon, France
| | | | | | | | | | | | | |
Collapse
|